Zuccato Biotech

Zuccato HC Biotech Division proposes itself as the interlocutor of the physician dealing with difficult wounds, providing a basket of products and materials of 100% biological origin for a totally regenerative approach to wound care, offering the clinician multiple therapeutic choices, single and combined, for an increasingly effective personalisation of care, always leaving the clinician the choice of the therapeutic option he/she deems most appropriate. Ever since its foundation, Zuccato HC Biotech Division has carried out extensive 'evangelisation' work on the possibilities offered by regenerative medicine, giving rise to more than 700 trials of regenerative technologies in 57 centres in 14 regions of Italy, in sectors ranging from traditional venous ulcers and diabetic foot ulcers to more niche areas such as the treatment of scleroderma and lichen vaginalis, as well as burns, dehiscences, traumatic lesions, osteomyelitis and bone infections in general. The basket of products that Zuccato HC makes available to the physician/surgeon includes various regenerative technologies, such as - Peripheral Blood Mono-Nucleated Cells (PB-MNC) - Microfractured Autologous Adipose Tissue (HADSC, Homologous Adipose-Derived Stem Cells) - Bioglass for Bone Regeneration in Infected Sites ("Bioglass") - Medical Device for Extracellular Matrix (RGTA, Regenerating Topical Agent) The company proposes itself as a partner in the distribution, technical information and commercial support of these technologies, all linked by the common thread of using biological materials to increase the body's natural endogenous healing capacity. In addition to scientific support, Zuccato HC provides its interlocutors with specific legal and regulatory support to safely address the various issues underlying the use of biotechnological medical products.